Results 71 to 80 of about 2,667 (188)

CLINICAL SPECTRUM AND THERAPEUTIC ADVANCES IN PEDIATRIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [PDF]

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder driven by somatic PIGA mutations, leading to uncontrolled complement activation, intravascular hemolysis, and thrombotic risk.
Anna Maria Pietrzak, Edyta Szymańska, Hubert Rycyk, Jakub Pysiewicz, Julia Prabucka-Marciniak, Kacper Kmieć, Kamila Zych, Marlena Rycyk, Mateusz Dembiński, Michał Bereza   +9 more
core   +2 more sources

Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis

Muscle &Nerve, Volume 73, Issue 2, Page 269-276, February 2026.
ABSTRACT Introduction/Aims Studies on pregnancy in myasthenia gravis (MG) are limited by small sample sizes or examine a limited number of outcomes. The objective of this study was to estimate the prevalence of perinatal and infant outcomes and characterize perinatal treatment patterns in MG.
Melanie H. Jacobson, Rupa Makadia, Ashley E. L. Anderson, Zia Choudhry, Nathan Hall, Jill Hardin, Sicong Huang, Janice M. Massey, Anna Ostropolets, Ran Sun, Rebecca Zaha, Alexis A. Krumme   +11 more
wiley   +1 more source

Invited letter MUC4 mutations as an amplifier of complement‐mediated thrombosis in paroxysmal nocturnal haemoglobinuria

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Eng Soo Yap, Edwin Wei Sheng Thong, Cheryl Xiu Qi Lim   +2 more
wiley   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data

BMC Nephrology
Background The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS).
Kristina Schönfelder, Lucas Kühne, Lena Schulte-Kemna, Jessica Kaufeld, Hana Rohn, Andreas Kribben, Bernd Schröppel, Paul T. Brinkkötter, Anja Gäckler   +8 more
doaj   +1 more source

Usage of Newer Immunotherapies in Myasthenic Crisis – A Review of the Literature [PDF]

non
Dang, Johnny, Li, Yuebing, Uysal, Sanem
core   +2 more sources

Impact of Symptoms of Neuromyelitis Optica Spectrum Disorder and Patient‐Determined Oral Glucocorticoid–Related Adverse Events on Patients' Daily Living and Emotions: A Qualitative Analysis From Japan

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Background and Objectives Neuromyelitis optica spectrum disorder (NMOSD) is a chronic disorder with a relapsing–remitting disease course that impacts patients' quality of life. Oral glucocorticoids (OGCs) have been the standard of care for NMOSD in Japan; however, their chronic use is associated with adverse events (AEs).
Yuko Shimizu, Ichiro Nakashima, Ryotaro Ikeguchi, Tadashi Nagatsuka, Katsuhisa Yamashita, Yuta Fukuoka, Tatsunori Murata, Kazuo Fujihara   +7 more
wiley   +1 more source

Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4‐IgG+ NMOSD Treated With Rituximab—A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS)

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this multicenter cohort study, we evaluated the risk of infection in people with AQP4‐IgG+ NMOSD treated with rituximab. We found no significant difference in infection risk between patients receiving rituximab and those treated with azathioprine.
Daniel Engels, Mariella Herfurth, Joachim Havla, Patrick Schindler, Klemens Ruprecht, Carolin Schwake, Marius Ringelstein, Katinka Fischer, Charlotte Schubert, Insa Schiffmann, Martin W. Hümmert, Katrin Giglhuber, Sven Jarius, Ioannis Vardakas, Matthias Grothe, Thorleif Etgen, Clemens Warnke, Jasmin Naumann, Frank Hoffmann, Makbule Senel, Brigitte Wildemann, Achim Berthele, Corinna Trebst, Vivien Häußler, Orhan Aktas, Ilya Ayzenberg, Judith Bellmann‐Strobl, Florian Then Bergh, Tania Kümpfel, Neuromyelitis Optica Study Group (NEMOS)   +29 more
wiley   +1 more source

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy [PDF]

Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti-C5 monoclonal antibody eculizumab was the first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at the price of a life ...
Fattizzo, Bruno, Versino, Francesco
core   +1 more source

Mild clinical course of covid-19 in 3 patients receiving therapeutic monoclonal antibodies targeting c5 complement for hematologic disorders [PDF]

, 2020
© Am J Case Rep, 2020. Objective: Rare co-existance of disease or pathology Background: Patients receiving immunosuppressive therapies might be more susceptible to COVID-19.
Araten, D. J., Iyengar, A., Mattoo, A., Michael Belmont, H., Reddy, R., Schaefer-Cutillo, J.   +5 more
core   +2 more sources